[Chemotherapy increases FcγRⅡB content in peripheral blood of the patients with lung squamous cell carcinoma].
To detect the FcγRⅡB content of monocytes and B cells,the concentration of soluble FcγRⅡB( s FcγRⅡB) and its antibodies in the peripheral blood of patients with lung squamous cell carcinoma( LSCC) before and after chemotherapy. The expression and localization of FcγR Ⅱ B on monocytes and B cells were detected by immunofluorescence technique; the expression of FcγR Ⅱ B mRNA was examined by quantitative real-time PCR; Western blotting was performed to detect the expression of FcγRⅡB protein; the serum concentrations of s FcγRⅡB,s FcγRⅡB-Ig G complex,anti-FcγRⅡB autoantibody were determined by ELISA. The expression of FcγRⅡB on monocytes and B cells,the total s FcγRⅡB and anti-FcγRⅡB antibody content in the sera of LSCC patients were lower than those in healthy volunteers. Chemotherapy enhanced the expression of FcγRⅡB both on the detected cell surface and in the peripheral blood of patients with LSCC,and increased the serum concentration of anti-FcγR Ⅱ B autoantibodies as well. In addition,the concentration of s FcγR Ⅱ B-Ig G in the peripheral blood was higher in LSCC patients than that in healthy volunteers,and it decreased after chemotherapy. The level of FcγRⅡB decreases in LSCC patients,but it rises after chemotherapy.